

Anal Canal Cancer

Effective Date: April, 2020



Background

The anal canal is delimited superiorly by the proximal extent of the levator-external anal sphincter complex and inferiorly by the anal verge (the junction between the anal mucosa and the hair-bearing skin). Lesions that involve the hair-bearing skin (peri-anal skin within 5 cm of the anal verge) are considered cancers of the anal margin and should also be treated as anal cancers.

This guideline was developed to outline the management recommendations for patients with squamous cell carcinomas that arise within the anal canal. Adenocarcinomas of the anal canal should be treated like rectal cancers (see the Early-Stage Rectal Cancer Clinical Practice Guideline).

Guideline Questions

1. What are the goals of therapy and recommendations for the treatment of adult patients with potentially curable cancer of the anal canal?
2. What are the recommendations for management of adult patients who have undergone curative therapy for cancer of the anal canal?
3. What are the recommendations for management of adult patients with locally recurrent cancer of the anal canal?
4. What are the recommendations for management of adult patients with metastatic cancer of the anal canal?

Search Strategy

Randomized controlled trials and systematic reviews, derived from an English language and relevant term search of PubMed and MEDLINE from 1990 forward. It takes into consideration related information presented at local, national, and international meetings as well as the Alberta Provincial Gastrointestinal Tumour Team's interpretation of the data.

Target Population

The recommendations outlined in this guideline apply to adults over the age of 18 years with squamous cell carcinomas that arise within the anal canal. Different principles may apply to pediatric patients.

Recommendations

Suggested Diagnostic Work-Up

The incidence of squamous cell carcinomas that arise within the anal canal has increased with the prevalence of Human Papilloma Virus (HPV) infection, Human Immunodeficiency Virus (HIV) infection, and immunosuppression required for organ transplantation. If the use of chemotherapy or radiotherapy is considered and HIV infection is suspected, HIV serology and an evaluation of the CD₄ count are suggested in addition to the complete blood count and both liver and renal function tests.

CT chest abdomen pelvis, MRI of the pelvis are recommended. The addition of a PET/CT scan to the staging workup has a significant impact on therapy planning, particularly identifying those patients who need higher-dose RT to the groin and those with otherwise occult metastatic disease. A meta-analysis of 12 studies concluded that a PET CT changed nodal status in 28% of patients and should be considered¹. Suspicious lymph nodes should be evaluated with a biopsy by fine-needle aspirate. Female patients should have a gynecological assessment (including a Pap smear) to exclude a synchronous cervical cancer. A colonoscopy should be performed to detect synchronous lesions.

Stage Information

Table 1. American Joint Committee on Cancer Staging Information, Eighth Edition.

Stage	Tumour Stage		Regional Lymph Node Involvement		Metastases	
0	T _{is}	High-grade squamous intraepithelial lesion (previously termed carcinoma in situ, Bowen disease, anal intraepithelial neoplasia II-III, high-grade anal intraepithelial neoplasia)	N ₀	No regional lymph node metastasis	M ₀	Absent
I	T ₁	Tumor ≤2 cm	N ₀	No regional lymph node metastasis	M ₀	Absent
IIA	T ₂	Tumor >2 cm but ≤5 cm	N ₀	No regional lymph node metastasis	M ₀	Absent
IIB	T ₃	Tumor >5 cm	N ₀	No regional lymph node metastasis	M ₀	Absent
IIIA	T ₁	Tumor ≤2 cm	N ₁	Metastasis in inguinal, mesorectal, internal iliac, or external iliac nodes	M ₀	Absent
IIIA	T ₂	Tumor >2 cm but ≤5 cm	N ₁	Metastasis in inguinal, mesorectal, internal iliac, or external iliac nodes	M ₀	Absent
IIIB	T ₄	Tumor of any size invading adjacent organ(s), such as the vagina, urethra, or bladder	N ₁	Metastasis in inguinal, mesorectal, internal iliac, or external iliac nodes	M ₀	Absent
IIIC	T ₃	Tumor >5 cm	N ₁	Metastasis in inguinal, mesorectal, internal iliac, or external iliac nodes	M ₀	Absent
IIIC	T ₄	Tumor of any size invading adjacent organ(s), such as the vagina, urethra, or bladder	N ₁	Metastasis in inguinal, mesorectal, internal iliac, or external iliac nodes	M ₀	Absent
IV	T _{any}	See above	N _{any}	See above	M ₁	Present

Goals of Therapy and Recommendations for Potentially Curable Cancer of the Anal Canal

1. To render the patient free of disease and to delay or prevent recurrence.
2. To improve the patient's quality of life (to eliminate tumour-related symptoms) and to preserve continence.

Consider treatment on a clinical trial, if available.

Table 2. Recommendations for Potentially Curable Cancer of the Anal Canal.

Stage	Recommendations
Stage 0	<ul style="list-style-type: none"> • Consider a wide local excision provided that surgical resection can be completed to achieve negative margins and to preserve continence (no involvement of the anal sphincter).
Stage I	<ul style="list-style-type: none"> • Consider a wide local excision provided that surgical resection can be completed to achieve negative margins and to preserve continence (no involvement of the anal sphincter). • Consider primary chemoradiotherapy (as described for stage II and III_A disease) if sphincter

Stage	Recommendations
	<p>preservation (maintenance of continence) is not possible with a wide local excision.</p> <ul style="list-style-type: none"> Consider an abdominoperineal resection for residual or recurrent disease.
Stage II Stage III_A	<ul style="list-style-type: none"> Primary chemoradiotherapy²⁻⁷ involves the sequential administration of Mitomycin C (10 to 12 mg/m² IV) followed by a continuous intravenous infusion of 5-Fluorouracil (4,000 mg/m² over ninety-six hours) during week one (and, possibly, week five) of a course of radiation (4,500 to 5,400 cGy to the perineum and regional lymph nodes). Randomized trials have used a single dose of Mitomycin C at 12 mg/m². This is an evidence based option that is also supported by real world data.⁸ This regimen requires placement of a central venous catheter (“CVC”) or a peripherally inserted central catheter (“PICC line”). Consider an abdominoperineal resection for residual or recurrent disease.
Stage III_B	<ul style="list-style-type: none"> Primary chemoradiotherapy (as described for stage II and III_A disease). Consider a boost, if indicated. Consultation with the multidisciplinary and surgical team should be sought to determine the role of further surgery.

Post-Curative Therapy Guidelines

- Perform a digital rectal examination and consider anoscopy at six to eight weeks after completion of the therapy. Consider biopsy of any suspicious lesions at three months after completion of therapy, but recognize that tumors may continue to respond up to six months after the radiation⁹.
- Perform salvage surgery for biopsy-proven persistent, progressive, or recurrent disease.
- After achieving a complete response, repeat digital rectal examination, anoscopy, and examination of the inguinal lymph nodes every four months for two years then every six months for the balance of five years.
- Female patients should have a gynecological assessment (including a Pap smear) due to the increased risk of cervical cancer. A colonoscopy should be obtained as outlined in the colorectal cancer screening guidelines.

Recommendations for Locally Recurrent Cancer of the Anal Canal

- For patients whose disease recurs despite prior radical chemoradiotherapy, consider surgical resection, if possible after repeating full staging investigations. Consider palliative therapy (see below) if surgical resection is not possible.
- For patients whose disease recurs after not having received prior chemoradiotherapy, consider radical chemoradiotherapy (see above) with or without surgery.

Goals of Therapy and Recommendations for Metastatic Cancer of the Anal Canal

- To maintain or to improve the patient’s quality of life (to control or to delay the onset of tumor-related symptoms).
- To prolong life, if possible.

Metastatic anal canal cancer describes the situation where a cancer that originated within the anal canal has spread beyond the regional lymph nodes to other organs. This represents an incurable situation for which palliative options (e.g.: best supportive care, palliative chemotherapy) may be considered.

Palliative chemotherapy regimens are generally continued as long as tumor shrinkage or stability is confirmed, as long as the side effects remain manageable, as long as the patient wishes to continue, and as long as the treatment remains medically reasonable.

Carboplatin/paclitaxel (Carboplatin AUC 5 on day 1 every 28 days and paclitaxel at 80 mg/m² on days 1, 8, 15 every 28 days). The InterAACT randomized phase II trial demonstrated the superiority of carboplatin/paclitaxel compared to cisplatin and infusional 5FU in inoperable, locally recurrent or metastatic SCC of the anal canal for overall survival (OS). OS was a secondary endpoint of this trial. Preliminary findings presented at ESMO 2018 demonstrated OS was 12.3 months with cisplatin/5FU versus 20 months with carboplatin and paclitaxel, hazard ratio [HR] 2.0 (p = 0.014). There was no difference in response rate, the primary endpoint of this trial (57.1% with cisplatin/5-FU compared to 59.0% with carboplatin/paclitaxel). Median PFS was 5.7 months for cisplatin/5-FU versus 8.1 months for carboplatin/paclitaxel (p = 0.375). The incidence of serious adverse events (SAEs) was lower with carboplatin/paclitaxel; SAEs were reported in 62% of cisplatin/5-FU patients compared with 36% of patients receiving carboplatin/paclitaxel (p = 0.016). There are no randomized phase III trials in this setting, and patients should be encouraged to participate in clinical trials¹⁰.

References

1. Jones M, Hruby G, Solomon M, Rutherford N, Martin J. The Role of FDG-PET in the Initial Staging and Response Assessment of Anal Cancer: A Systematic Review and Meta-analysis. *Ann Surg Oncol* 2015 Oct;22(11):3574-3581.
2. Ajani JA, Winter KA, Gunderson LL, Pedersen J, Benson AB, 3rd, Thomas CR, Jr, et al. Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. *JAMA* 2008 Apr 23;299(16):1914-1921.
3. Bartelink H, Roelofsens F, Eschwege F, Rougier P, Bosset JF, Gonzalez DG, et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. *J Clin Oncol* 1997 May;15(5):2040-2049.
4. Flam M, John M, Pajak TF, Petrelli N, Myerson R, Doggett S, et al. Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. *J Clin Oncol* 1996 Sep;14(9):2527-2539.
5. James RD, Glynn-Jones R, Meadows HM, Cunningham D, Myint AS, Saunders MP, et al. Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 x 2 factorial trial. *Lancet Oncol* 2013 May;14(6):516-524.
6. Peiffert D, Tournier-Rangear L, Gerard JP, Lemanski C, Francois E, Giovannini M, et al. Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: final analysis of the randomized UNICANCER ACCORD 03 trial. *J Clin Oncol* 2012 Jun 1;30(16):1941-1948.
7. Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research. *Lancet* 1996 Oct 19;348(9034):1049-1054.
8. White EC, Goldman K, Aleshin A, Lien WW, Rao AR. Chemoradiotherapy for squamous cell carcinoma of the anal canal: Comparison of one versus two cycles mitomycin-C. *Radiother Oncol* 2015 Nov;117(2):240-245.
9. Glynn-Jones R, James R, Meadows H, Begum R, Cunningham D, Northover J, et al. Optimum time to assess complete clinical response (CR) following chemoradiation (CRT) using mitomycin (MMC) or cisplatin (CisP), with or without maintenance CisP/5FU in squamous cell carcinoma of the anus: results of ACT II. *J Clin Oncol* 2012 ASCO Annual Meeting Proceedings 2012;30(suppl; abstr 4004).
10. Rao S, Sclafani F, Eng C, Grønlie Guren M, Adams RA, Benson A, et al. LBA21InterAACT: A multicentre open label randomised phase II advanced anal cancer trial of cisplatin (CDDP) plus 5-fluorouracil (5-FU) vs carboplatin (C) plus weekly paclitaxel (P) in patients (pts) with inoperable locally recurrent (ILR) or metastatic treatment naïve disease - An International Rare Cancers Initiative (IRCI) trial. *annonc* 2018;29(suppl_8):mdy424.022.

Development and Revision History

This guideline was reviewed and endorsed by the Alberta GI Tumour Team. Members include surgical oncologists, radiation oncologists, medical oncologists, gastroenterologists, nurses, pathologists, and pharmacists. Evidence was selected and reviewed by a working group comprised of members from the Alberta Tumour Teams, external participants identified by the Working Group Lead, and a knowledge management specialist from the Guideline Resource Unit. A detailed description of the methodology followed during the guideline development process can be found in the [Guideline Resource Unit Handbook](#).

This guideline was originally developed in 2008, and updated in 2010, 2011, 2013, and 2020.

Levels of Evidence

I	Evidence from at least one large randomized, controlled trial of good methodological quality (low potential for bias) or meta-analyses of well-conducted randomized trials without heterogeneity
II	Small randomized trials or large randomized trials with a suspicion of bias (lower methodological quality) or meta-analyses of such trials or of trials with demonstrated heterogeneity
III	Prospective cohort studies
IV	Retrospective cohort studies or case-control studies
V	Studies without control group, case reports, expert opinion

Strength of Recommendations

A	Strong evidence for efficacy with a substantial clinical benefit; strongly recommended
B	Strong or moderate evidence for efficacy but with a limited clinical benefit; generally recommended
C	Insufficient evidence for efficacy or benefit does not outweigh the risk or the disadvantages (adverse events, costs, etc.); optional
D	Moderate evidence against efficacy or for adverse outcome; generally not recommended
E	Strong evidence against efficacy or for adverse outcome; never recommended

Maintenance

A formal review of the guideline will be conducted in 2021. If critical new evidence is brought forward before that time, however, the guideline working group members will revise and update the document accordingly.

Abbreviations

CT, Computerized Tomography; HIV, Human Immunodeficiency Virus; HPV, Human Papilloma Virus; HR, Hazard Ratio; MRI, Magnetic Resonance Imaging; OS, Overall Survival; PET, Positron Emission Tomography; RT, Radiotherapy; SAE, Serious Adverse Events; SCC, Squamous Cell Carcinoma

Disclaimer

The recommendations contained in this guideline are a consensus of the Alberta Provincial GI Tumour Team and are a synthesis of currently accepted approaches to management, derived from a review of relevant scientific literature. Clinicians applying these guidelines should, in consultation with the patient, use independent medical judgment in the context of individual clinical circumstances to direct care.

Copyright © (2020) Alberta Health Services

This copyright work is licensed under the [Creative Commons Attribution-NonCommercial-NoDerivative 4.0 International license](#). You are free to copy and distribute the work including in other media and formats for non-commercial purposes, as long as you attribute the work to Alberta Health Services, do not adapt the work, and abide by the other license terms. To view a copy of this license, see <https://creativecommons.org/licenses/by-nc-nd/4.0/>.

The license does not apply to AHS trademarks, logos or content for which Alberta Health Services is not the copyright owner.

Funding Source

Financial support for the development of CancerControl Alberta's evidence-based clinical practice guidelines and supporting materials comes from the CancerControl Alberta operating budget; no outside commercial funding was received to support the development of this document.

All cancer drugs described in the guidelines are funded in accordance with the Outpatient Cancer Drug Benefit Program, at no charge, to eligible residents of Alberta, unless otherwise explicitly stated. For a complete list of funded drugs, specific indications, and approved prescribers, please refer to the [Outpatient Cancer Drug Benefit Program Master List](#).

Conflict of Interest Statements

Dr. Andrew Scarfe has nothing to disclose.

Dr. Dan Schiller has nothing to disclose.

Dr. Patricia Tang reports receiving grants from Pfizer and Roche, and other support from Amgen, Taiho, AstraZeneca and Genomic Health.

Derek Tilley has nothing to disclose.